Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome

BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of ophthalmology Vol. 83; no. 10; pp. 1121 - 1124
Main Authors Condon, Patrick I, McEwen, Charles G, Wright, Mark, Mackintosh, Graeme, Prescott, Robin J, McDonald, Carolyn
Format Journal Article
LanguageEnglish
Published BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.10.1999
BMJ
BMJ Publishing Group LTD
Subjects
Online AccessGet full text
ISSN0007-1161
1468-2079
DOI10.1136/bjo.83.10.1121

Cover

Loading…
Abstract BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. METHODS A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days’ treatment, subjects crossed over to the other study medication for a further 28 days’ treatment. RESULTS 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer’s score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. CONCLUSION The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.
AbstractList BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. METHODS A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days’ treatment, subjects crossed over to the other study medication for a further 28 days’ treatment. RESULTS 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer’s score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. CONCLUSION The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.
Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome.BACKGROUND/AIMSHyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome.A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment.METHODSA randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment.70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported.RESULTS70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported.The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.CONCLUSIONThe study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.
Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment. 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.
BACKGROUND/AIMS —Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome.
 METHODS —A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment.
 RESULTS —70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported.
 CONCLUSION —The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.
Author Condon, Patrick I
McDonald, Carolyn
Prescott, Robin J
McEwen, Charles G
Wright, Mark
Mackintosh, Graeme
AuthorAffiliation Ardkeen Hospital, Waterford, Ireland
AuthorAffiliation_xml – name: Ardkeen Hospital, Waterford, Ireland
Author_xml – sequence: 1
  givenname: Patrick I
  surname: Condon
  fullname: Condon, Patrick I
– sequence: 2
  givenname: Charles G
  surname: McEwen
  fullname: McEwen, Charles G
– sequence: 3
  givenname: Mark
  surname: Wright
  fullname: Wright, Mark
– sequence: 4
  givenname: Graeme
  surname: Mackintosh
  fullname: Mackintosh, Graeme
– sequence: 5
  givenname: Robin J
  surname: Prescott
  fullname: Prescott, Robin J
– sequence: 6
  givenname: Carolyn
  surname: McDonald
  fullname: McDonald, Carolyn
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1976063$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10502570$$D View this record in MEDLINE/PubMed
BookMark eNqFUl1v0zAUjdAQ6wavPCJLfGiVls6OGzt9QUIdBaRpSDDGo-XYDnVx7GI7hfw8_hlOW8aYhHiw7Ot7zrnn-vooO7DOqix7jOAEIUzO6pWbVHiyDQt0LxuhKanyAtLZQTaCENIcIYIOs6MQViksCKIPskMES1iUFI6yn-euq40CtdFWngLPrXStDiqd14YLVTsgnI3eGTPcCe9CcBvlT0HbmaiFSjkFQuxkD6IDUkXlW20ViEsFVNNowUUPXAM4SBafg5PvZ5sxCE7qrgXLnpvOO8tjknCmi9pZcLJICnyjgxgDbbc6qQSPbSo1CEnfA9UnQm-ld616mN1vuAnq0X4_zj4tXl_N3-YX79-8m7-6yOsSlTFvaFVVVCEBkYKYF4JKPG2IgGUjmpmUEFVKUCoJmWJMSo4lLqum4qSs8EwUBT7OXu50113dKrntnBu29rrlvmeOa_Z3xuol--I2DNGiqPAg8GIv4N23ToXI0kMLZQy3ynWBkVkBywLDBHx6B7hynbepuaRFZ2lNMU2oJ7f93Bj5PdsEeLYH8CC4adJshQ5_cDNKIMEJNtnBtrP1qrmlxIY_xtIfYxXehQVKhOkdgtCRD7NLbWvzb1q-o-kQ1Y-bItx_ZYRiWrLL6zk7v_744fLz4ooNvsY7fN2u_mfpF_Kl9E4
CODEN BJOPAL
CitedBy_id crossref_primary_10_1038_s41598_017_08534_5
crossref_primary_10_1016_j_ajo_2005_05_025
crossref_primary_10_1016_j_carres_2020_107950
crossref_primary_10_3390_ijerph18052383
crossref_primary_10_1007_s40123_017_0110_x
crossref_primary_10_3390_nu8110750
crossref_primary_10_1089_108076803321908400
crossref_primary_10_1185_03007995_2015_1125871
crossref_primary_10_1111_cxo_12073
crossref_primary_10_1016_j_rbre_2015_08_002
crossref_primary_10_1097_ICL_0000000000000236
crossref_primary_10_1016_j_colsurfb_2016_01_014
crossref_primary_10_1016_j_clae_2014_09_002
crossref_primary_10_2174_1573412915666190304142952
crossref_primary_10_1038_eye_2017_272
crossref_primary_10_3341_jkos_2023_64_2_170
crossref_primary_10_1016_j_rbr_2015_07_004
crossref_primary_10_3390_genes12030365
crossref_primary_10_1002_mabi_201700261
crossref_primary_10_1007_s00417_004_1040_6
crossref_primary_10_1038_nrrheum_2016_100
crossref_primary_10_1517_13543784_2013_838557
crossref_primary_10_3390_ijms20164031
crossref_primary_10_1097_OPX_0000000000002172
crossref_primary_10_1089_jop_2018_0151
crossref_primary_10_1007_s00432_022_04241_5
crossref_primary_10_1007_s13346_024_01570_5
crossref_primary_10_1002_jbm_a_32481
crossref_primary_10_3390_molecules22122104
crossref_primary_10_1007_s00417_005_0028_1
crossref_primary_10_1016_j_bjps_2007_03_005
crossref_primary_10_1097_ICO_0b013e3181d82f5e
crossref_primary_10_1016_j_clae_2013_07_004
crossref_primary_10_1016_j_clae_2017_07_007
crossref_primary_10_1097_ICO_0000000000000155
crossref_primary_10_1097_OPX_0b013e318182476c
crossref_primary_10_1016_S0161_6420_02_01219_8
crossref_primary_10_1097_OPX_0000000000002136
crossref_primary_10_1038_srep10248
crossref_primary_10_1111_aos_15675
crossref_primary_10_1155_2014_635490
crossref_primary_10_1111_aos_15159
crossref_primary_10_1016_j_ajpath_2011_10_006
crossref_primary_10_1080_10837450_2024_2345148
crossref_primary_10_1517_14656566_2010_518612
crossref_primary_10_1111_j_1444_0938_2001_tb04930_x
crossref_primary_10_1097_ICL_0000000000000284
crossref_primary_10_1111_j_1475_1313_2009_00683_x
crossref_primary_10_1016_j_ophtha_2012_12_022
crossref_primary_10_1016_S0142_9612_01_00167_3
crossref_primary_10_1038_nrrheum_2012_53
crossref_primary_10_1038_sj_eye_6700169
ContentType Journal Article
Copyright British Journal of Ophthalmology
1999 INIST-CNRS
Copyright: 1999 British Journal of Ophthalmology
Copyright_xml – notice: British Journal of Ophthalmology
– notice: 1999 INIST-CNRS
– notice: Copyright: 1999 British Journal of Ophthalmology
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
BTHHO
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1136/bjo.83.10.1121
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
BMJ Journals
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
BMJ Journals
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
ProQuest One Academic Middle East (New)
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2079
EndPage 1124
ExternalDocumentID PMC1722832
4012639221
10502570
1976063
10_1136_bjo_83_10_1121
ark_67375_NVC_DVSRNWFT_3
bjophthalmol
Genre Multicenter Study
Comparative Study
Clinical Trial
Randomized Controlled Trial
Journal Article
GeographicLocations Edinburgh Scotland
GeographicLocations_xml – name: Edinburgh Scotland
GroupedDBID ---
-~X
.55
.GJ
.VT
0R~
18M
23N
2WC
354
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
ABAAH
ABJNI
ABKDF
ABMQD
ABTFR
ABUWG
ABVAJ
ACCCW
ACGFO
ACGFS
ACGTL
ACHTP
ACMFJ
ACNCT
ACOAB
ACOFX
ACQSR
ACTZY
ADBBV
ADCEG
ADZCM
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
BAWUL
BENPR
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DU5
E3Z
EBS
EJD
F5P
FYUFA
H13
HAJ
HMCUK
HYE
HZ~
IAO
IEA
IHR
IOF
ITC
J5H
KQ8
L7B
M1P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
W8F
WH7
WOQ
X7M
XOL
YFH
YQY
ZGI
3V.
BSCLL
RHF
AAFWJ
AAYXX
ACQHZ
AERUA
CITATION
PHGZM
IQODW
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-b515t-f78887e1c01e03a2c7d34f6c05fcf9dd018ec77d6643365a3d358f8a65839c223
IEDL.DBID BENPR
ISSN 0007-1161
IngestDate Thu Aug 21 14:06:33 EDT 2025
Thu Sep 04 17:28:00 EDT 2025
Fri Jul 25 06:22:02 EDT 2025
Thu Jan 02 23:04:31 EST 2025
Mon Jul 21 09:14:13 EDT 2025
Thu Apr 24 23:10:07 EDT 2025
Tue Jul 01 01:47:43 EDT 2025
Wed Oct 30 09:15:11 EDT 2024
Thu Apr 24 23:02:39 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Human
Sodium Compounds
Dry eye syndrome
Local administration
Eye disease
Chemotherapy
Ophthalmic preparation
Randomization
Treatment
Multicenter study
Organic salt
Double blind study
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b515t-f78887e1c01e03a2c7d34f6c05fcf9dd018ec77d6643365a3d358f8a65839c223
Notes href:bjophthalmol-83-1121.pdf
istex:2D01DC55025071EB02B3FD1795CA030943A9F699
local:bjophthalmol;83/10/1121
PMID:10502570
Carolyn McDonald, Fermentech Medical Ltd, Research Avenue South, Heriot Watt Research Park, Edinburgh EH14 4AP.
ark:/67375/NVC-DVSRNWFT-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://bjo.bmj.com/content/bjophthalmol/83/10/1121.full.pdf
PMID 10502570
PQID 1779177437
PQPubID 2041039
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_1722832
proquest_miscellaneous_69205230
proquest_journals_1779177437
pubmed_primary_10502570
pascalfrancis_primary_1976063
crossref_primary_10_1136_bjo_83_10_1121
crossref_citationtrail_10_1136_bjo_83_10_1121
istex_primary_ark_67375_NVC_DVSRNWFT_3
bmj_primary_10_1136_bjo_83_10_1121
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1999-10-01
PublicationDateYYYYMMDD 1999-10-01
PublicationDate_xml – month: 10
  year: 1999
  text: 1999-10-01
  day: 01
PublicationDecade 1990
PublicationPlace BMA House, Tavistock Square, London, WC1H 9JR
PublicationPlace_xml – name: BMA House, Tavistock Square, London, WC1H 9JR
– name: London
– name: England
PublicationTitle British journal of ophthalmology
PublicationTitleAlternate Br J Ophthalmol
PublicationYear 1999
Publisher BMJ Publishing Group Ltd
BMJ
BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group Ltd
– name: BMJ
– name: BMJ Publishing Group LTD
References Fukuda, Miyamoto, Miyara 1998; 10
Tsubota, Yamada 1992; 33
Yokoi, Komuro, Nishida 1997; 81
Stuart, Linn 1985; 17
Hamano, Horimoto, Lee 1996; 40
Polack, McNiece 1982; 1
Nishida, Nakamura, Mishima 1991; 53
Hills, Armitage 1979; 8
Shimmura, Ono, Shinozaki 1995; 79
Van Bijsterweld 1969; 82
Mengher, Pandher, Bron 1986; 70
Sand, Marner, Norn 1989; 67
Wysenbeek, Loya, Sira 1988; 29
Prescott 1981; 30
Ke-Ping, Yukiko, Tsubota 1996; 15
Nakamura, Hikida, Nakano 1993; 12
References_xml – volume: 1
  start-page: 133
  year: 1982
  article-title: The treatment of dry eyes with Na hyaluronate (Healon).
  publication-title: Cornea
– volume: 30
  start-page: 9
  year: 1981
  article-title: The comparison of success rates in cross-over trials in the presence of an order effect.
  publication-title: Appl Stat
– volume: 10
  start-page: 20
  year: 1998
  article-title: Hyaluronic acid in tear fluid and its synthesis by corneal epithelial cells.
  publication-title: Asia-Pacific J Ophthalmol
– volume: 40
  start-page: 62
  year: 1996
  article-title: Sodium hyaluronate eyedrops enhance tear film stability.
  publication-title: Jpn J Ophthalmol
– volume: 15
  start-page: 235
  year: 1996
  article-title: Decrease in corneal sensitivity and change in tear function in dry eye.
  publication-title: Cornea
– volume: 33
  start-page: 2942
  year: 1992
  article-title: Tear evaporation from the ocular surface.
  publication-title: Invest Ophthalmol Vis Sci
– volume: 70
  start-page: 442
  year: 1986
  article-title: Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes.
  publication-title: Br J Ophthalmol
– volume: 79
  start-page: 1007
  year: 1995
  article-title: Sodium hyaluronate eye drops in the treatment of dry eyes.
  publication-title: Br J Ophthalmol
– volume: 17
  start-page: 190
  year: 1985
  article-title: Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders.
  publication-title: Ann Ophthalmol
– volume: 67
  start-page: 181
  year: 1989
  article-title: Sodium hyaluronate in the treatment of keratoconjunctivitis sicca.
  publication-title: Acta Ophthalmol
– volume: 29
  start-page: 194
  year: 1988
  article-title: The effect of sodium on the corneal epithelium.
  publication-title: Invest Ophthalmol Vis Sci
– volume: 53
  start-page: 753
  year: 1991
  article-title: Hyaluronan stimulates corneal epithelial migration.
  publication-title: Exp Eye Res
– volume: 81
  start-page: 533
  year: 1997
  article-title: Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye.
  publication-title: Br J Ophthalmol
– volume: 12
  start-page: 433
  year: 1993
  article-title: Characterization of water retentive properties of hyaluronan.
  publication-title: Cornea
– volume: 82
  start-page: 10
  year: 1969
  article-title: Diagnostic tests in the sicca syndrome.
  publication-title: Arch Ophthalmol
– volume: 8
  start-page: 7
  year: 1979
  article-title: The two-period cross-over clinical trial.
  publication-title: Br J Clin Pharmacol
SSID ssj0002617
Score 1.8596932
Snippet BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study...
Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the...
BACKGROUND/AIMS —Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
istex
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1121
SubjectTerms Adult
Aged
Biological and medical sciences
Cell adhesion & migration
clinical trial
Cross-Over Studies
Double-Blind Method
dry eye
Dry Eye Syndromes - drug therapy
Eye
Female
Humans
Hyaluronan
Hyaluronic Acid - therapeutic use
Male
Medical sciences
Middle Aged
Molecular weight
Ophthalmic Solutions
Original articles - Clinical science
Patient Satisfaction
Patients
Pharmacology. Drug treatments
Preferences
Sodium
Sodium Chloride - therapeutic use
Studies
Treatment Outcome
Title Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome
URI http://bjo.bmj.com/content/83/10/1121.full
https://api.istex.fr/ark:/67375/NVC-DVSRNWFT-3/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/10502570
https://www.proquest.com/docview/1779177437
https://www.proquest.com/docview/69205230
https://pubmed.ncbi.nlm.nih.gov/PMC1722832
Volume 83
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1tb9MwELZYKyG-IN4X2IqFeNmkZU3iJHY-IRirJqRVaGyj3yzHdrSOLhlNO-jP459xdtxsRbx8axvn4saXu-fOT-4QekmiTKpYFX6ulfJjITOfscQ0M0tzFYgkE6F5OflwmB6cxB9Hycgl3GpHq1zaRGuoVSVNjrwfUgqRBfg7-vbym2-6RpndVddCYw11wQSzpIO67_eHn45aW2zqjTcAmPohgBtXtjEkaT8_r3YZ2W3eognBteQX5yvOqWvu8w9DlhQ13K-iaXTxJyT6O6Hyhoca3EN3HbTE7xpduI9u6fIBun3oNs8fop8AlvOJxjkgS7WD4UKqglXW8Nkys_IKO-L6xPxmp2gInjvYsg7tVTW29WjxrMLKEWk0BgyJtSlFIeQCVwUWGP7tK7z1vX-1jetKjecX-GwhJvOpSdWDCKfueGtg_MLVuJbbeFxaOS3x3QhS0wXWCzjBlVV4hE4G-8d7B77r4ODngJNmfmECbKpDGYQ6ICKSVJG4SGWQFLLIlApCpiWlKgVcRNJEEEUSVjABsIhkEpDLY9Qpq1KvI6wjwSC4iVieQlCjFFM0CWVMAfHouKCph17AAvLLpkYHt7ENSTmsMmek-RqFHvKX68ulq4FuWnFM_jr-TTv-f5JfW3Vph4npV8OZowkfnu7xD6efj4ZfBseceGhzRZ-u5QIwBLzooY2lfnFnTmp-rfweet4eBhUxuzui1NW85mkW2RS_h540ynhjxklgmhV6iK6oaTvAlBhfPVKOz2ypcYC3ppfV039P6hm6Y6tZWI7jBurMpnO9CVhtlvfQGh3RnnssezaZ9gsTYUFl
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLYQlba9TOyeAcOaxgYSoUmcxMnDNG1AVQatJlYub55jO6KsJKxpYf1T-w_7Zzt20kCnXZ54axvXcXWOz_lO_eU7CL0iXiykL1M7UVLaPhexHUWBbmYWJtLhQcxd_XBypxu2D_2PJ8HJHPoxfRZG0yqnMdEEapkL_R9506UUKgvId_TdxTdbd43Sp6vTFhqlW-ypyRWUbMXb3W2w76rntXZ6W2276ipgJ5C7R3aqiz6qXOG4yiHcE1QSPw2FE6QijaV03EgJSmUIuZqEASeSBFEacUjVJBaeFjqAkN8AmBHDLmp82Ol-Oqhjv9Y3LwE3tV0AU5VMpEvCZnKWb0Zks3xqx4VUlpyfzSTDhrbrd03O5AXYJy0ba_wJ-f5O4LyREVsL6H4FZfH70vceoDmVPUR3OtVh_SP0E8B5MlA4ASQrNzDcSObgVQpeGyZYkuOKKD_Qn5klakLpBjYsR3NXhY3-LR7lWFbEHYUBs2KlpS-4mOA8xRzDr13Fa1fNy3Vc5LI_PsenEz4YD_XRAExRbS-81tJ56LJfiHXcz8w8NdFeTySHE6wm8IVKxuExOrwV2z5B81meqWcIK49HUEx5URJCESVlJGngCp8CwlJ-SkMLvQQDsotSE4SZWoqEDKzMIlK-9VwL2VP7MlFpruvWH4O_jn9Tj__fzK-Nu9TD-PCr5ujRgHWPttj20eeD7nGrx4iFlmf86XpeAKKATy20NPUvVoWvgl1vNgut1JfBRfRpEs9UPi5YGHvmSMFCT0tnvLHiwNHNES1EZ9y0HqAlzWevZP1TI20OcFr3znr-70WtoLvtXmef7e929xbRPaOkYfiVS2h-NByrZcCJo-RFtTkx-nLb8eAXsiB7iw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLZQK6G9TLsvGwxrGhtIhCZxEicP07RRKhijQozbm-fYjigrCWtaWP_a3vbPduy4hU67PPHWNq7j6pyc853683cQekWCVMhQ5m6mpHRDLlI3SSLdzCzOpMejlPv6cPJuN946DD-eRCdz6MfkLIymVU5iognUshT6P_KWTylUFpDvaCu3tIi9dufdxTdXd5DSO62Tdhq1i-yo8RWUb9Xb7TbYejkIOpsHG1uu7TDgZpDHh26uC0CqfOH5yiM8EFSSMI-FF-UiT6X0_EQJSmUMeZvEESeSREmecEjbJBWBFj2A8N-kkBWTBmp-2Ozu7U_zgNY6r8E3dX0AVlYy0idxKzsr1xOyXp_g8SGtZednM4mxqW38XRM1eQW2yusmG39Cwb-TOW9kx849dNfCWvy-9sP7aE4VD9D8rt24f4h-AlDP-gpngGrlGoYbyRI8TMFrwwrLSmxJ8339mVmiJpeuYcN4NHdV2Gjh4mGJpSXxKAz4FSstg8HFGJc55hh-7TJeuWpdruKqlL3ROT4d8_5ooLcJYAr7qOGVjs5Jl71KrOJeYeaZku71RHIwxmoMX7CSDo_Q4a3Y9jFqFGWhniKsAp5AYRUkWQwFlZSJpJEvQgpoS4U5jR30EgzILmp9EGbqKhIzsDJLSP028B3kTuzLhNVf121A-n8d_2Y6_n8zvzbuMh3GB181X49GrHu0wdpHn_e7x50DRhy0OONP1_MCKAWs6qCFiX8xG8oqdv3gOWhpehlcRO8s8UKVo4rFaWC2Fxz0pHbGGyuOPN0o0UF0xk2nA7S8-eyVondqZM4BWus-Ws_-vaglNA9xgH3a7u48R3eMqIahWi6gxnAwUosAGYfZC_tsYvTltsPBL1Zqf7c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Double+blind%2C+randomised%2C+placebo+controlled%2C+crossover%2C+multicentre+study+to+determine+the+efficacy+of+a+0.1%25+%28w%2Fv%29+sodium+hyaluronate+solution+%28Fermavisc%29+in+the+treatment+of+dry+eye+syndrome&rft.jtitle=British+journal+of+ophthalmology&rft.au=Condon%2C+Patrick+I&rft.au=McEwen%2C+Charles+G&rft.au=Wright%2C+Mark&rft.au=Mackintosh%2C+Graeme&rft.date=1999-10-01&rft.issn=0007-1161&rft.eissn=1468-2079&rft.volume=83&rft.issue=10&rft.spage=1121&rft_id=info:doi/10.1136%2Fbjo.83.10.1121&rft_id=info%3Apmid%2F10502570&rft.externalDBID=bjo&rft.externalDocID=bjophthalmol
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1161&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1161&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1161&client=summon